FairJourney Biologics has successfully completed the acquisition of Charles River Laboratories' antibody discovery and engineering site in San Francisco, US.
The facility, which is positioned in one of the world's most prevalent biotech clusters, will strengthen FairJourney's antibody discovery capabilities, as well as its biotech presence within the key US market.
All staff, facilities and assets at the site will also be transferred to FairJourney — which includes a range of trademarked antibody libraries.
By combining the US facility's tech with its own range of antibody discovery tools, FairJourney will be able to offer its customers a more diverse array of antibody services.
Under the terms of the agreement, Charles River will also hand over its Yeast Display method.
By expanding its operations into the thriving San Francisco biotech cluster, the company hopes to provide customers in the region with localised expertise and technical support, which will be carried out by the team previously under Charles River.
“We’re pleased to announce this strategic acquisition that will bring the exceptional team at Charles River’s South San Francisco site, as well as their cutting-edge technologies, into FairJourney.” Said António Parada, CEO, FairJourney Biologics.
“By combining our expertise, we not only strengthen our portfolio with powerful solutions such as the SuperHuman Libraries, but also enhance our ability to deliver innovative solutions to our partners. Working together, we can push the boundaries of antibody discovery and set new industry standards.”